Gastric cancer is one of the most common cancers worldwide, and the prognosis is still very poor due to the lack of specific and sensitive biomarkers. Aerobic glycolysis is one of the critical hallmarks of gastric cancer cells, and several glycolytic enzymes are highly expressed in gastric cancer patients. However, the expression and clinical significances of phosphofructokinase-2/fructose-2,6-bisphosphatase3 (PFKFB3, one of the glycolytic enzymes) in a large sample of gastric cancer patients remain unclear.
METHODS:
The expression of PFKFB3 was detected in 134 gastric cancer patients by qRT-PCR, immunohistochemistry, and western blot analyses. The correlation between PFKFB3 expression and clinicopathological factors was analyzed by χ 2 test. In addition, we also analyzed whether the knockdown of PFKFB3 by siRNAs could inhibit the ability of gastric cancer cells (MGC-803 and AGS) to proliferate and migrate by MTT analysis and transwell analyses.
RESULTS:
PFKFB3 was highly expressed in 81.3% (109/134) of gastric cancer patients. The overexpression of PFKFB3 was associated with lymph node metastasis (P = 0.045) and TNM stage (P = 0.033). Knockdown of PFKFB3 by siRNAs significantly inhibited the proliferation and migration abilities of gastric cancer cells.
CONCLUSION:
Our data suggest that PFKFB3 might be a potential biomarker for gastric cancer and anti-neoplastic targeting gene.
ChenW., ZhengR., BaadeP.D., ZhangS., ZengH., BrayF., JemalA., YuX.Q., HeJ., Cancer statistics in China, 2015, CA Cancer J Clin. 66 (2016) 115-132.
2.
ZhuL., QinJ., WangJ., GuoT., WangZ., YangJ., Early Gastric Cancer: Current Advances of Endoscopic Diagnosis and Treatment, Gastroenterol Res Pract. 2016 (2016) 9638041.
DurãesC., AlmeidaG.M., SerucaR., OliveiraC., CarneiroF., Biomarkers for gastric cancer: prognostic, predictive or targets of therapy, Virchows Arch. 464 (2014) 367-378.
5.
EmotoS., IshigamiH., YamashitaH., YamaguchiH., KaisakiS., KitayamaJ., Clinical significance of CA125 and CA72-4 in gastric cancer with peritoneal dissemination, Gastric Cancer. 15 (2012) 154-161.
6.
KandaM., FujiiT., TakamiH., SuenagaM., InokawaY., YamadaS., NakayamaG., SugimotoH., KoikeM., NomotoS., KoderaY., Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients, Surg. Today. 44 (2014) 1692-1701.
7.
LeungW.K., WuM.S., KakugawaY., KimJ.J., YeohK.G., GohK.L., WuK.C., WuD.C., SollanoJ., KachintornU., GotodaT., LinJ.T., YouW.C., NgE.K., SungJ.J., Screening for gastric cancer in Asia: current evidence and practice, Lancet Oncol. 9 (2008) 279-287.
8.
WarburgO., On the origin of cancer cells, Science. 123 (1956) 309-314.
9.
YamadaA., OguchiK., FukushimaM., ImaiY., KadoyaM., Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression, Ann Nucl Med. 20 (2006) 597-604.
10.
QiuM.Z., HanB., LuoH.Y., ZhouZ.W., WangZ.Q., WangF.H., LiY.H., XuR.H., Expressions of hypoxia-inducible factor-1α and hexokinase-II in gastric adenocarcinoma: the impact on prognosis and correlation to clinicopathologic features, Tumour Biol. 32 (2011) 159-166.
11.
YinL., WangX., LuoC., LiuH., ZhangL., ZhangH., ZhangY., The value of expression of M2-PK and VEGF in patients with advanced gastric cancer, Cell Biochem. Biophys. 67 (2013) 1033-1039.
12.
Van SchaftingenE., LedererB., BartronsR., HersH.G., A kinetic study of pyrophosphate: fructose-6-phosphate phosphotransferase from potato tubers. Application to a microassay of fructose 2,6-bisphosphate, Eur. J. Biochem. 129 (1982) 191-195.
13.
YalcinA., TelangS., ClemB., ChesneyJ., Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer, Exp. Mol. Pathol. 86 (2009) 174-179.
14.
AtsumiT., ChesneyJ., MetzC., LengL., DonnellyS., MakitaZ., MitchellR., BucalaR., High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers, Cancer Res. 62 (2002) 5881-5887.
15.
ChesneyJ., MitchellR., BenigniF., BacherM., SpiegelL., Al-AbedY., HanJ.H., MetzC., BucalaR., An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: role in tumor cell glycolysis and the Warburg effect, Proc. Natl. Acad. Sci. U.S.A.96 (1999) 3047-3052.
16.
ClemB., TelangS., ClemA., YalcinA., MeierJ., SimmonsA., RaskuM.A., ArumugamS., DeanW.L., EatonJ., LaneA., TrentJ.O., ChesneyJ., Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth, Mol. Cancer Ther. 7 (2008) 110-120.
17.
HanJ., MengQ., XiQ., ZhangY., ZhuangQ., HanY., JiangY., DingQ., WuG., Interleukin-6 stimulates aerobic glycolysis by regulating PFKFB3 at early stage of colorectal cancerInt. J. Oncol. 48 (2016) 215-224.
18.
FléjouJ.F., [WHO Classification of digestive tumors: the fourth edition], Ann Pathol. 31 (2011) S27-31.
19.
TanP., YeohK.G., Genetics and Molecular Pathogenesis of Gastric Adenocarcinoma, Gastroenterology. 149 (2015) 1153-1162.e3.
20.
AllumW.H., BlazebyJ.M., GriffinS.M., CunninghamD., JankowskiJ.A., WongR., Guidelines for the management of oesophageal and gastric cancer, Gut. 60 (2011) 1449-1472.
21.
AtsumiT., ChesneyJ., MetzC., LengL., DonnellyS., MakitaZ., MitchellR., BucalaR., High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers, Cancer Res. 62 (2002) 5881-5887.
22.
VanderH.M.G., CantleyL.C., ThompsonC.B., Understanding the Warburg effect: The metabolic requirements of cell proliferation, Science. 324 (2009) 1029-1033.
23.
DohertyJ.R., ClevelandJ.L., Targeting lactate metabolism for cancer therapeutics, J. Clin. Invest. 123 (2013) 3685-3692.
24.
CairnsR.A., HarrisI.S., MakT.W., Regulation of cancer cell metabolism, Nat. Rev. Cancer. 11 (2011) 85-95.
25.
YounesM., BrownR.W., StephensonM., GondoM., CagleP.T., Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival, Cancer. 80 (1997) 1046-1051.
26.
YounesM., JuarezD., LechagoL.V., LernerS.P., Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival, Anticancer Res. 21 (2001) 575-578.
27.
AlakusH., BaturM., SchmidtM., DrebberU., BaldusS.E., VallböhmerD., PrenzelK.L., MetzgerR., BollschweilerE., HölscherA.H., MönigS.P., Variable 18F-fluorodeoxyglucose uptake in gastric cancer is associated with different levels of GLUT-1 expression, Nucl Med Commun. 31 (2010) 532-538.
28.
YamadaA., OguchiK., FukushimaM., ImaiY., KadoyaM., Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in gastric carcinoma: relation to histological subtypes, depth of tumor invasion, and glucose transporter-1 expression, Ann Nucl Med. 20 (2006) 597-604.
29.
LuntS.Y., VanderH.M.G., Aerobic glycolysis: meeting the metabolic requirements of cell proliferation, Annu. Rev. Cell Dev. Biol. 27 (2011) 441-464.
30.
CalvoM.N., BartronsR., CastañoE., PeralesJ.C., Navarro-SabatéA., ManzanoA., PFKFB3 gene silencing decreases glycolysis, induces cell-cycle delay and inhibits anchorage-independent growth in HeLa cells, FEBS Lett. 580 (2006) 3308-3314.
31.
OsthusR.C., ShimH., KimS., LiQ., ReddyR., MukherjeeM., XuY., WonseyD., LeeL.A., DangC.V., Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc, J. Biol. Chem. 275 (2000) 21797-21800.
32.
KondohH., LleonartM.E., GilJ., WangJ., DeganP., PetersG., MartinezD., CarneroA., BeachD., Glycolytic enzymes can modulate cellular life span, Cancer Res. 65 (2005) 177-185.
33.
KimJ.W., DangC.V., Cancer's molecular sweet tooth and the Warburg effect, Cancer Res. 66 (2006) 8927-8930.
34.
López-LázaroM., HIF-1: hypoxia-inducible factor or dysoxia-inducible factor, FASEB J. 20 (2006) 828-832.
35.
MarsinA.S., BouzinC., BertrandL., HueL., The stimulation of glycolysis by hypoxia in activated monocytes is mediated by AMP-activated protein kinase and inducible 6-phosphofructo-2-kinase, J. Biol. Chem. 277 (2002) 30778-30783.
ClemB.F., O'NealJ., TapolskyG., ClemA.L., Imbert-FernandezY., KerrD.A., KlarerA.C., RedmanR., MillerD.M., TrentJ.O., TelangS., ChesneyJ., Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer, Mol. Cancer Ther. 12 (2013) 1461-1470.
38.
LeaM.A., GuzmanY., DesbordesC., Inhibition of Growth by Combined Treatment with Inhibitors of Lactate Dehydrogenase and either Phenformin or Inhibitors of 6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase 3, Anticancer Res. 36 (2016) 1479-1488.
